![A researcher holds a vial of the ChAdOx1 coronavirus vaccine while a trial volunteer sits in the background](https://www.ox.ac.uk/sites/files/oxford/styles/ow_medium_feature/s3/VACCINELEAD-SQUARE-Jenner_Institute_by_John_Cairns_20.11.20-41.jpg?itok=W88nOE5y)
The Oxford COVID-19 vaccine trial was designed to test a new COVID-19 vaccine in health volunteers as well as to assess how well people across a broad age range could be protected from COVID-19 with this new vaccine.
Oxford University breakthrough on global COVID-19 vaccine
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Read the full article on the Oxford University news page.